D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy prognostic significance for the success of anti-cancer treatment

Mirshahi, S.; Pujade-Lauraine, Éric; Soria, Claudine; Mirshahi, Massoud; Fretault, J.; Bernadou, A

doi:10.1002/1097-0142(19920501)69:9<2289::aid-cncr2820690914>3.0.co;2-a

Cited by 36 publications

(33 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 It is a sensitive marker of the fibrinolytic enhancement. 32 As in many other human malignancies, [33][34][35][36][37][38] including lung carcinoma, DD might have prognostic significance. 12,15,39 In 1993, Seitz et al 12 reported that TAT and DD were significantly increased in patients with metastatic disease and that elevated TAT values at diagnosis might be prognostically significant.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of D‐dimer in lung carcinoma

Buccheri

Torchio

Ferrigno

2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe activation of the clotting‐fibrinolytic system in cancer patients is common and represents an unfavorable clinical sign. D‐dimer (DD) is a sensitive marker of fibrinolysis.METHODSThe current study comprised 826 new lung carcinoma patients seen consecutively in a single institution over a 10‐year period (1992–2001). For each patient, 31 variables, including DD and survival duration, were available for analysis.RESULTSOnly weak relationships between DD and the other variables were found. The DD variable correlated best with the level of lactate dehydrogenase, performance status, tissue polypeptide antigen, stage of disease, and the number of metastases (rho = 0.33, −0.25, 0.18, 0.18, and 0.15, respectively). The D‐dimer distinguished patients with different prognoses. The median survival periods were 154 days (95% confidence interval [CI], 122–189 days) and 308 days (95% CI, 227–409 days; log rank statistic, 26.56; P < 0.01), respectively, for abnormally elevated and normal values. The difference was greater in patients with adenocarcinoma and in patients presenting with a less advanced disease, especially in patients with pathologic Stage Ia disease. The best multivariate survival model selected 10 significant covariates, including DD.CONCLUSIONSThe authors recommend measuring the plasma level of DD in all new lung carcinoma patients. This measurement may help to formulate individual prognoses and can be used to indicate adjuvant treatment for surgical patients. Cancer 2003;97:3044–52. © 2003 American Cancer Society.DOI 10.1002/cncr.11432

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma levels of D‐dimer in lung carcinoma

Buccheri

Torchio

Ferrigno

2003

Cancer

View full text Add to dashboard Cite

show abstract

“…16 Interestingly, plasma D-dimer levels have been shown to correlate with tumor markers such as CA-125 in ovarian cancer 32,33 and carcinoembryonic antigen in colorectal cancer. 18 The latter study demonstrated that high D-dimer levels predicted disease progression and overall survival better than carcinoembryonic antigen did, indicating that assays of D-dimer may serve as a useful strategy for disease monitoring in patients undergoing therapy.…”

Section: © F E R R a T A S T O R T I F O U N D A T I O Nmentioning

confidence: 99%

High D-dimer levels are associated with poor prognosis in cancer patients

Dunkler²,

Pirker³

et al. 2012

Haematologica

286

244

View full text Add to dashboard Cite

“…Wieding and colleagues (93) found no differences in mean antithrombin levels and activities in 57 women with advanced breast cancer before, compared to after, receiving one cycle of different chemotherapy regimens. During five cycles of cisplatinum doxorubicin 5 fluorouracil chemotherapy in 26 ovarian cancer patients in FIGO stage III and IV Mirshahi et al (105) serially determined D-dimer where mean levels decreased in 8 patients but remained unchanged and above normal in 18. No information about DVT was given.…”

Section: Chemotherapymentioning

confidence: 99%

State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy

Gf¹,

Pollow²,

Schneider³

et al. 1999

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

The occurrence of deep vein thrombosis (DVT) in gynecologic cancer patients has a multifactorial genesis.Besides the older age of patients and the coexistence of additional thrombosis favoring illnesses such as obesity, hypertension, metabolic and cardiovascular disorders, and others, therapeutic management can be an independent risk factor for DVT. Radical surgery for pelvic genital cancer leads to an incidence of postoperative DVT between 6% in ovarian cancer and up to 20% in cervical or endometrial cancer patients (1). The rate for DVT after breast cancer surgery does not exceed 3 % (2-4) and breast cancer patients under observation were found to experience DVT at a rate of 0% to 3.28% (5-7) compared to an overall incidence per year of about 0.3% in women (8). Radiotherapy, especially during intrauterine/ vaginal radium application for 12 to 24 hours, in uterine cancer patients has a reported rate between 2.5% and 6.8%. These rates occur whether or not thrombosis prophylaxis with either a daily dose of low molecular weight heparin (LMWH) administered subcutaneously or oral anticoagulation with warfarin was given (9-11). In a recent postmortem study (12), among 966 consecutive autopsies with thrombosis and/or pulmonary embolism (PE), cancer was coincident in 56% of cases. Breast cancer (5.7%) and cervical cancer (2.4%) were among the four most frequent cancer types and were significantly over represented when compared to a control group of 325 consecutive and unselected autopsies without DVT (3.1 % and 0.6%; p < .05).The most comprehensive data on thrombotic complications in gynecologic malignancy were drawn from studies of breast cancer patients in association with cytoreductive therapy and showed an approximate average incidence of 5%. These results are substantial since most patients with breast and ovarian cancer will receive chemotherapy for adjuvant and/or palliative settings some time in the course of their disease.Deep vein thrombosis is a frequent complication in gynecologic malignancy and should be considered when planning therapeutic management of patients. This article discusses the prethrombotic state and the rate of thrombotic complications in patients receiving standard cytoreductive therapy for breast and ovarian cancer and the possible mechanisms of chemotherapy-induced thrombosis. The results of recent thrombosis prevention trials are summarized.

show abstract

D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy prognostic significance for the success of anti-cancer treatment

Cited by 36 publications

References 12 publications

Plasma levels of D‐dimer in lung carcinoma

Plasma levels of D‐dimer in lung carcinoma

High D-dimer levels are associated with poor prognosis in cancer patients

State-of-the-Art Review : Chemotherapy and Thrombosis in Gynecologic Malignancy

Contact Info

Product

Resources

About